LICENSE AND TRANSFER AGREEMENTLicense and Transfer Agreement • June 28th, 2016 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • New York
This license and transfer agreement (the “Agreement”) is entered into with effect as of April 18, 2016 (the “Effective Date”) by and between Pieris Pharmaceuticals, Inc., a Nevada corporation with a place of business at 255 State Street, 9th Floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a German company with a place of business at Lise-Meitner-Strasse 30, 85354 Freising, Germany (collectively and together with their Affiliates, “Pieris”) and Enumeral Biomedical Holdings, Inc., a Delaware corporation with a place of business at 200 CambridgePark Drive, Suite 2000, Cambridge, MA 02140 (together with its Affiliates, “Enumeral”).
Standard Contracts
CONFIDENTIAL TREATMENT REQUESTED LICENSE AND TRANSFER AGREEMENTLicense and Transfer Agreement • July 20th, 2016 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
This license and transfer agreement (the “Agreement”) is entered into with effect as of April 18, 2016 (the “Effective Date”) by and between Pieris Pharmaceuticals, Inc., a Nevada corporation with a place of business at 255 State Street, 9th Floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a German company with a place of business at Lise-Meitner-Strasse 30, 85354 Freising, Germany (collectively and together with their Affiliates, “Pieris”) and Enumeral Biomedical Holdings, Inc., a Delaware corporation with a place of business at 200 CambridgePark Drive, Suite 2000, Cambridge, MA 02140 (together with its Affiliates, “Enumeral”).
License and Transfer Agreement by and between GlaxoSmithKline (China) R&D Co., Ltd and Zai Lab (Shanghai) Co., Ltd. October 18, 2016License and Transfer Agreement • August 15th, 2017 • Zai Lab LTD • Pharmaceutical preparations
This License and Transfer Agreement (this “Agreement”), dated as of October 18, 2016 (the “Effective Date”), is made by and between GlaxoSmithKline (China) R&D Co., Ltd, a foreign invested enterprise duly established and validly existing under PRC law, whose registered office is at Building 3, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, PRC (“GSK”) and Zai Lab (Shanghai) Co., Ltd., a company duly organized and validly existing under PRC law, whose registered office is at 1043 Halei Road, Bldg 8, Suite 502, Zhangjiang Hi-Tech Park, Shanghai, PRC (“Zai Lab”). GSK and Zai Lab are each referred to herein individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED DEFINITIVE LICENSE AND TRANSFER AGREEMENTLicense and Transfer Agreement • August 11th, 2016 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
This Definitive License and Transfer Agreement (the “Agreement”) is entered into with effect as of June 6, 2016 (the “Effective Date”) by and between Pieris Pharmaceuticals, Inc., a Nevada corporation with a place of business at 255 State Street, 9th Floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a German company with a place of business at Lise-Meitner-Strasse 30, 85354 Freising, Germany (collectively and together with their Affiliates, “Pieris”) and Enumeral Biomedical Holdings, Inc., a Delaware corporation with a place of business at 200 CambridgePark Drive, Suite 2000, Cambridge, MA 02140 (together with its Affiliates, “Enumeral”).
ContractLicense and Transfer Agreement • April 22nd, 2022
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
License and Transfer Agreement for IL-21 ProteinLicense and Transfer Agreement • May 6th, 2009 • Zymogenetics Inc • Biological products, (no disgnostic substances) • Washington
This License and Transfer Agreement for IL-21 Protein (“Agreement”) is effective as of January 16, 2009 (the “Effective Date”) and is entered into by and between ZymoGenetics, Inc., a Washington corporation having a principal place of business at 1201 Eastlake Avenue East, Seattle, Washington 98102 (“ZGEN”), and Novo Nordisk A/S, a Danish corporation having a principal place of business at Novo Alle, DK-2880, Bagsvaerd, Denmark (“NN”).
LICENSE AND TRANSFER AGREEMENTLicense and Transfer Agreement • March 29th, 2021 • GX Acquisition Corp. • Pharmaceutical preparations • New York
This LICENSE AND TRANSFER AGREEMENT (this “Agreement”) is made as of September 30, 2020 (the “Effective Date”), by and between Sorrento Therapeutics, Inc., a Delaware corporation (“Sorrento”), and Celularity Inc., a Delaware corporation (“Celularity”).
2 3 1.10 Escrow Agreement. "Escrow Agreement" shall have the meaning given such term in Section 4.3(b) hereof.License and Transfer Agreement • March 28th, 1996 • I Flow Corp /Ca/ • Surgical & medical instruments & apparatus • California
LICENSE AND TRANSFER AGREEMENTLicense and Transfer Agreement • August 12th, 2016 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • New York
This Definitive License and Transfer Agreement (the “Agreement”) is entered into with effect as of June 6, 2016 (the “Effective Date”) by and between Pieris Pharmaceuticals, Inc., a Nevada corporation with a place of business at 255 State Street, 9th Floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a German company with a place of business at Lise-Meitner-Strasse 30, 85354 Freising, Germany (collectively and together with their Affiliates, “Pieris”) and Enumeral Biomedical Holdings, Inc., a Delaware corporation with a place of business at 200 CambridgePark Drive, Suite 2000, Cambridge, MA 02140 (together with its Affiliates, “Enumeral”).
LICENSE AND TRANSFER AGREEMENTLicense and Transfer Agreement • November 9th, 2017 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
This LICENSE AND TRANSFER AGREEMENT (this “Agreement”) is made as of August 15, 2017 (the “Effective Date”), by and between TNK Therapeutics, Inc., a Delaware corporation and a majority owned subsidiary of Sorrento Therapeutics, Inc. (“TNK”), Sorrento Therapeutics, Inc. a Delaware corporation (“Sorrento”), and Celularity, Inc., a Delaware corporation (“Celularity”).
LICENSE AND TRANSFER AGREEMENTLicense and Transfer Agreement • March 30th, 2005 • Ucn Inc • Telephone communications (no radiotelephone) • Utah
This License and Transfer Agreement is effective the 1st day of October 2003, and is made by and between the Ion Group, L.C., a Utah limited liability company (“Ion”) and MyACD Inc., a Utah corporation (“MyACD”).